Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

More measles cases have been reported in Washington state. Officials in Seattle-King County yesterday reported two measles ...